A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)

被引:0
作者
Glen J Weiss
Jordan Waypa
Lisa Blaydorn
Jessica Coats
Kayla McGahey
Ashish Sangal
Jiaxin Niu
Cynthia A Lynch
John H Farley
Vivek Khemka
机构
[1] Western Regional Medical Center,
[2] Cancer Treatment Centers of America,undefined
来源
British Journal of Cancer | 2017年 / 117卷
关键词
pembrolizumab; immunotherapy; chemotherapy; clinical trial; phase I; advanced/metastatic solid tumours;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:33 / 40
页数:7
相关论文
共 288 条
[1]  
Bigelow E(2013)Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue J Vis Exp 71 4059-32
[2]  
Bever KM(2014)Immunological off-target effects of standard treatments in gastrointestinal cancers Ann Oncol 25 24-247
[3]  
Xu H(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-233
[4]  
Yager A(2012)The secret ally: immunostimulation by anticancer drugs Nat Rev Drug Discov 11 215-88
[5]  
Wu A(2016)Immune checkpoint inhibitors in non-small cell lung cancer Oncologist 22 81-1508
[6]  
Taube J(2013)Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas PLoS One 8 e82870-2520
[7]  
Chen L(2016)Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study Lancet Oncol 17 1497-720
[8]  
Jaffee EM(2015)PD-1 blockade in tumors with mismatch-repair deficiency N Engl J Med 372 2509-3943
[9]  
Anders RA(2009)Dose escalation methods in phase I cancer clinical trials J Natl Cancer Inst 101 708-2979
[10]  
Zheng L(2013)Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements Clin Cancer Res 19 3936-1117